All In Biotech

Free tool

FAERS Monitor: Menostar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021674 or its brand name (Menostar, Estradiol). Reports on generic versions are filed under their own applications.

Reports

47,042

Serious

22,534

48% of reports

Hospitalization

7,231

Death reported

909

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective3,830
  • headache2,889
  • nausea2,877
  • fatigue2,870
  • off label use2,399
  • pain2,081
  • diarrhoea1,955
  • dizziness1,728
  • breast cancer female1,708
  • arthralgia1,636
  • product adhesion issue1,582
  • pruritus1,558
  • rash1,538
  • dyspnoea1,526
  • vomiting1,348

Reports by year received

View as table
YearReports
2004524
2005571
2006406
20071,465
2008466
2009608
2010958
2011858
20121,156
2013879
20141,113
20151,912
20162,328
20172,136
20182,487
20192,872
20202,878
20212,831
20223,054
20233,554
20243,703
20255,251
20265,031

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,007,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
breast cancer femaleSignal1,70830.529.045,605
product adhesion issueSignal1,58220.719.728,326
headacheSignal2,8892.12.01,627
pruritus1,5581.81.7579
arthralgia1,6361.81.7547
fatigue2,8701.71.6761
nausea2,8771.61.6720
rash1,5381.61.5332
dizziness1,7281.61.5345
pain2,0811.51.5375
diarrhoea1,9551.41.3187
drug ineffective3,8301.31.3282
vomiting1,3481.31.285
off label use2,3991.21.2103
dyspnoea1,5261.21.155

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.